Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress
October 11, 2023 07:00 ET
|
Tiziana Life Sciences Ltd.
Treatment Of Six Non-Active Secondary Progressive MS With Nasal Anti-CD3 Monoclonal Antibody (Foralumab): Safety, Biomarker, And Disability Outcomes
Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis
September 26, 2023 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Targeted Therapeutics Market Size & Share to Surpass $80.9 Billion by 2030 | Vantage Market Research
September 19, 2023 09:13 ET
|
Vantage Market Research
WASHINGTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- As per Vantage Market Research, the Global Targeted Therapeutics Market has been steadily growing over the years due to the increasing prevalence of...
Breaking Into a Saturated Relapsing Remitting Multiple Sclerosis Market: Where Should Developers Focus?
August 01, 2023 12:02 ET
|
Spherix Global Insights
Exton, Pennsylvania, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Despite outward appearances of being a stagnant market, the relapsing remitting multiple sclerosis (RMS) market continues to offer drug...
Autoinjectors Market to Grow at 16.2% CAGR and Reach USD 3.8 Bn by 2031 | Excusive Research by Transparency Market Research
June 15, 2023 10:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, June 15, 2023 (GLOBE NEWSWIRE) -- The global autoinjectors market was valued at USD 1.0 Bn in 2022 and is projected to grow at a CAGR of 16.2% from 2023 to 2031....
Tiziana Life Sciences Announces Reduction in Microglial Activation in a Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis
June 05, 2023 10:00 ET
|
Tiziana Life Sciences Ltd.
Results confirm positive signal previously reported in the first two Expanded Access patients who both subsequently demonstrated clinical improvementsPhase 2a trial in na-SPMS on track to begin in Q3...
Tiziana Life Sciences to Host KOL Webinar on Foralumab in Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
May 25, 2023 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Global Multiple Sclerosis Drugs Market Sales to Top US$ 41 Billion by 2033; CAGR of 3.8%
May 12, 2023 02:33 ET
|
Market.Us
New York, May 12, 2023 (GLOBE NEWSWIRE) -- According to Market.us, the global Multiple Sclerosis Drugs Market is estimated to be valued at USD 41 Billion by 2032 and is expected to exhibit a CAGR of...
Global Multiple Sclerosis Treatment Market Report 2023: Sector is Projected to Reach $38.41 Million in 2031 at a CAGR of 4.3%
May 03, 2023 10:53 ET
|
Research and Markets
Dublin, May 03, 2023 (GLOBE NEWSWIRE) -- The "Global Multiple Sclerosis Treatment Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.The global...
NeurologyLive® and CMSC Announce Giants of Multiple Sclerosis® 2023 Class of Inductees
April 26, 2023 09:19 ET
|
NeurologyLive
CRANBURY, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- NeurologyLive® and the Consortium of Multiple Sclerosis Centers (CMSC) are pleased to announce the 2023 Giants of Multiple Sclerosis® inductees. ...